Table 1 Patients characteristics
From: Systemic treatment in patients with malignant pleural mesothelioma – real life experience
No. of patients N = 57 (%) | |
|---|---|
Sex | |
Female | 16 (28) |
Male | 41 (72) |
Age (years) | |
Median, range | 64.2 (33–83) |
ECOG performance status | |
0 9 | (15.8) |
1 41 | (72) |
2 7 | (12.2) |
Histological subtype | |
Epithelial | 42 (73.7) |
Biphasic | 5 (8.8) |
Sarcomatoid | 2 (3.5) |
Not available | 8 (14) |
Stage | |
III 45 | (78.9) |
IV | 12 (21.1) |
Surgery: | |
yes | 11 (20) |
no | 46 (80) |
First-line therapy | 57 |
Pemetrexed-based | 55 (96.5) |
With platinum | 48 (87.3) |
Without platinum | 7 (12.7) |
Not pemetrexed-based | 2 (3.5) |
With platinum | 2 (100) |
Response to first-line therapy | |
CR/PR | 20 (35.1) |
SD | 27 (47.4) |
PD | 9 (15.8) |
vNot available | 1 (1.7) |
PFS after first-line therapy | |
< 6 months | 14 (24.6) |
≥ 6 months | 29 (50.9) |
< 12 months | 43 (75.4) |
≥ 12 months | 14 (24.6) |
Second-line therapy | 12 |
Pemetrexed-based | 7 (58.3) |
Non pemetrexed-based | 5 (41.7) |